R.E.N.A.L. nephrometry score predicts treatment efficacy

R.E.N.A.L. nephrometry score predicts treatment efficacy
The R.E.N.A.L. (radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior and location relative to polar lines) nephrometry scoring system predicts the efficacy of treatment and major complications that occur after percutaneous renal ablation for treatment of tumors, according to research published in the January issue of The Journal of Urology.

(HealthDay)—The R.E.N.A.L. (radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior and location relative to polar lines) nephrometry scoring system predicts the efficacy of treatment and major complications that occur after percutaneous renal ablation for treatment of tumors, according to research published in the January issue of The Journal of Urology.

Grant D. Schmit, M.D., of the Mayo Clinic in Rochester, Minn., and colleagues applied the R.E.N.A.L. criteria to 751 renal tumors in 627 patients to examine the correlation with oncological outcomes and complications after percutaneous ablation. Fifty-seven percent of tumors were treated with cryoablation and 43 percent were treated with radio frequency ablation.

The researchers found that the mean score for renal tumors treated with was significantly higher than for those treated with radio frequency ablation (7.2 ± 1.9 versus 6.1 ± 1.8). Over an average follow-up period of 27.9 months, 28 local treatment failures occurred. R.E.N.A.L. nephrometry score was significantly associated with local , with a mean score of 7.6 ± 2.2 in cases of failure versus 6.7 ± 1.9 in cases without failure. R.E.N.A.L. score was also significantly associated with major complications, with a mean score of 8.1 ± 2.0 in cases with a major complication versus 6.8 ± 1.9 in cases without a major complication.

"The R.E.N.A.L. nephrometry predicts oncological outcomes and complications following percutaneous renal ablation," the authors write. "As such, this tool may be used to facilitate the standardization of comparisons of treatment efficacy and safety across various approaches to small renal tumors."

One author disclosed to the medical device and technology industries.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Gluten-free diet benefits asymptomatic EmA+ adults

1 minute ago

(HealthDay)—Asymptomatic individuals with endomysial antibodies (EmA) benefit from a gluten-free diet (GFD), according to a study published in the September issue of Gastroenterology.

Another US health worker infected with Ebola

18 minutes ago

A third American health worker has tested positive for the Ebola virus while working with patients in West Africa, the Christian missionary group SIM said Tuesday.

UN implores all countries to help on Ebola

2 hours ago

The international group Doctor Without Borders warned Tuesday that the world is 'losing the battle' against Ebola, while U.N. officials implored all countries to quickly step up their response by contributing health experts ...

Travel restrictions could worsen Ebola crisis: experts

6 hours ago

Travel restrictions could worsen West Africa's Ebola epidemic, limiting medical and food supplies and keeping out much-needed doctors, virologists said Tuesday as the disease continued its deadly spread.

World 'losing battle' to contain Ebola: MSF (Update)

7 hours ago

International medical agency Medecins sans Frontieres said Tuesday the world was "losing the battle" to contain Ebola as the United Nations warned of severe food shortages in the hardest-hit countries.

User comments